DenmarkDenmark

Exiqon secures Euro17m in round C

10.07.2005

Copenhagen - The Danish real-time PCR specialist Exiqon A/S has completed a third round of financing at the beginning of June providing some Euro17 million in additional funding. The funding is earmarked for developing products from the company's growing product portfolio, for increasing sales and marketing capabilities and for repaying loans. This brings the total funding since incorporation in 1996 to Euro31 million. The current investors include Teknoinvest as lead investor and Scandinavian Life Science Venture, Nobel Group, LD Pensions, BioFund, and Danske Bank, all of which participated in the previous round of financing.
The company has recently completed a major distribution agreement with Roche Diagnostics for Exiqon's ProbeLibrary™ real-time PCR kits, addressing one of the largest market segments within life science. Exiqon is now strengthening its product portfolio as well as sales and marketing efforts and is launching a number of new miRCURY™ products for microRNA analysis as well as products in other high-growth areas. “Getting high-value products on the market is essential to our business and it has been the main focus for Exiqon during the past couple of years” says Exiqon's President and CEO Lars Kongsbak.

DenmarkDenmark

16.09.2006

Glostrup – Zealand Pharma A/S, a biopharmaceutical company developing peptide based drugs, has raised DKK216 million (a29 million) in a rights issue through the sale of about 5.7 million shares. According to the company, the deal...

DenmarkDenmark

21.07.2006

Copenhagen – Danish Curalogic raised Euro25 million through the sale of 2.5 million shares at the Copenhagen Stock Exchange on June 2. Meanwhile, Swedish biotech Respiratorios postponed the announced IPO to a later ungiven date.

DenmarkDenmark

21.07.2006

Copenhagen – Osteologix A/S has completed a reverse merger and share exchange transaction with publicy-held Castle & Morgan Holdings, Inc., based in New York, US. In parallel with the merger, the Copenhagen-based...

DenmarkDenmark

21.07.2006

Copenhagen – Curalogic A/S, a biotech company developing oral immunotherapeutic allergy treatments, has entered the Copenhagen Stock Exchange at the end of May, raising about Euro25 million. Likely to be added to this are DKK14...

DenmarkDenmark

21.07.2006

Hørsholm/Strasbourg – 7TM Pharma A/S, a spin-off from the University of Copenhagen, has acquired CareX SA, a privately held French company based in Strasbourg, France, for an unknown sum.CareX’ lead program utilizes a novel...

DenmarkDenmark

21.07.2006

Baggsvaerd – The world-leader in enzymes Novozymes A/S in Denmark has acquired the UK-based Delta Biotechnology Ltd. from the Sanofi-Aventis group for an unknown sum. The British company has 106 employees and is involved in...

DenmarkDenmark

12.05.2006

Copenhagen - The Danish government is proposing to allocate an extra Euro1 billion to research from 2007 to 2010. In addition, Euro200 million have been earmarked to be invested in innovation. The plan will allow Denmark reach...

DenmarkDenmark

12.05.2006

Vaterløse/Hørsholm - Three Danish biopharmaceutical companies have attracted several million euros of investment which will allow them to further the clinical development of their drug candidates. Hørsholm-based biopharmaceutical...

DenmarkDenmark

12.05.2006

Marseille/Copenhagen - The French biopharmeutical company Innate Pharma SA and the Danish diabetes care world leader Novo Nordisk have entered into a strategic partnership to develop new drugs targeting natural killer (NK) cells,...

Displaying results 101 to 110 out of 194

< Previous 101-110 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/10/article/exiqon-secures-euro17m-in-round-c.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products